Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Allen Chen, MD, PhD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Intervention

Cyclophosphamide(drug)

Eligibility

22 years · All sexes

Timeline

2015 – 2024

Study locations (1)

• Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT02602769
  Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
  Columbia University
• RECRUITINGNCT03135730
  International Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry
  Debra Weese-Mayer

See all trials for Rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome →